Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy
August 14, 2014 10:38 ET
|
Scienta Communications
NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Christopher Kiritsy to the Company's
Board of Directors. Mr. Kiritsy is currently president,...
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
August 11, 2014 12:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced top-line results of a Phase 1 clinical study that
demonstrated that the administration of single doses of...
ContraFect Corporation Announces Closing of Initial Public Offering
August 04, 2014 07:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Aug 4, 2014) - ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious...
ContraFect Announces Pricing of Its Initial Public Offering
July 29, 2014 07:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Jul 29, 2014) - ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious...
Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
July 24, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that the company and investigators will be making eight
presentations at the annual Interscience Conference...
Journal of Infectious Diseases Publishes ContraFect Corporation's Scientific Research
May 13, 2014 08:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 13, 2014) - ContraFect Corporation, a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening,...
Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections
May 05, 2014 11:27 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that patient enrollment has commenced in a Phase 3 trial
of oral and intravenous (I.V.) delafloxacin, a...
ContraFect Corporation Confirms Appointment of Julia P. Gregory as CEO and Director, and Appoints David N. Low, Michael J. Otto and Roger J. Pomerantz to Board of Directors
April 24, 2014 08:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Apr 24, 2014) - ContraFect Corporation, a leader in the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant...
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
February 10, 2014 07:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...
Melinta Therapeutics to Present at J.P. Morgan Healthcare Conference
January 09, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be providing a corporate and clinical update...